Oligonucleotide (Antisense oligonucleotide) · Gene silencing: clusterin (CLU) · developed by Achieve Life Sciences
Custirsen is an antisense oligonucleotide that blocks production of clusterin (TRPM-2), an anti-apoptotic protein overexpressed in prostate cancer cells. By reducing clusterin levels, custirsen sensitizes cancer cells to chemotherapy. It is studied in castrate-resistant prostate cancer and non-small cell lung cancer, typically combined with chemotherapy agents.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT01630733 | Phase 3 | Non-Small Cell Lung Cancer | Completed | ACHV |
| NCT01083615 | Phase 3 | Castrate-Resistant Prostate Cancer | Terminated | ACHV |
| NCT00327340 | Phase 2 | Prostate Cancer | Completed | ACHV |
| NCT01497470 | Phase 1 | Cancer | Completed | ACHV |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
CancerCastrate-Resistant Prostate CancerHormone Refractory Prostate CancerNon-Small Cell Lung CancerProstate Cancer
Updated Oct 3, 2026. Something wrong or missing? Report it on the ACHV page.
See ACHV's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ACHV catalysts and pipeline →